Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 26, 2021 11:50am
56 Views
Post# 33267876

RE:RE:Melphalen flufenamide

RE:RE:Melphalen flufenamideIt's already lunched under the brand name Pepaxto, grossed US $2.3 M in the first two weeks.

https://stockhouse.com/companies/bullboard/t.th/theratechnologies-inc?postid=33266771

qwerty22 wrote:

On the stock front. Oncopeptides spiked in Mar on approval to a market cap close to 2 billion USD and since have drifter back to 1 billion. I wonder what sort of discussion is going on in Swedish chat boards about valuations?

 

qwerty22 wrote: We must have mentioned melphalen flufenamide, a PDC that got approval recently.

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple-myeloma

Pretty small trial. Data summarized in table.

https://sparkcures.com/treatment/264/melphalan-flufenamide

There's no question PDCs can work, it's about proving th1902 has activity.

 

 

 



<< Previous
Bullboard Posts
Next >>